Gene · 104
Papers2,137
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,137
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pre-mRNA splicing and its cotranscriptional connections. | Trends Genet | 2023 | 37236814 | PubTator, text mining | PubMed |
| Attenuation of Dopaminergic Neurodegeneration in a C. elegans Parkinson's Model through Regulation of Xanthine Dehydrogenase (XDH-1) Expression by the RNA Editase, ADR-2. | J Dev Biol | 2023 | 37218814 | PubTator, text mining | PubMed |
| Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. | Signal Transduct Target Ther | 2023 | 37217462 | PubTator, text mining | PubMed |
| RNA editing of AZIN1 coding sites is catalyzed by ADAR1 p150 after splicing. | J Biol Chem | 2023 | 37209819 | PubTator, text mining | PubMed |
| ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer. | Nat Commun | 2023 | 37208334 | PubTator, text mining | PubMed |
| Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox. | Biochemistry | 2023 | 37192099 | PubTator, text mining | PubMed |
| CRISPR-Cas System: The Current and Emerging Translational Landscape. | Cells | 2023 | 37190012 | PubTator, text mining | PubMed |
| Editorial for the Special Issue-"Recent Advances of Novel Pharmaceutical Designs for Anti-Cancer Therapies". | Int J Mol Sci | 2023 | 37175966 | PubTator, text mining | PubMed |
| Development and evaluation of an adenosine-to-inosine RNA editing-based prognostic model for survival prediction of bladder cancer patients. | Medicine (Baltimore) | 2023 | 37171335 | PubTator, text mining | PubMed |
| Universality in RNA and DNA deformations induced by salt, temperature change, stretching force, and protein binding. | Proc Natl Acad Sci U S A | 2023 | 37155848 | PubTator, text mining | PubMed |
| Exercise Promotes Tissue Regeneration: Mechanisms Involved and Therapeutic Scope. | Sports Med Open | 2023 | 37149504 | PubTator, text mining | PubMed |
| Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer. | Front Genet | 2023 | 37124622 | PubTator, text mining | PubMed |
| Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update. | Noncoding RNA | 2023 | 37104009 | PubTator, text mining | PubMed |
| The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation. | Immunity | 2023 | 37100060 | PubTator, text mining | PubMed |
| Host A-to-I RNA editing signatures in intracellular bacterial and single-strand RNA viral infections. | Front Immunol | 2023 | 37081881 | PubTator, text mining | PubMed |
| DeepEdit: single-molecule detection and phasing of A-to-I RNA editing events using nanopore direct RNA sequencing. | Genome Biol | 2023 | 37069604 | PubTator, text mining | PubMed |
| The SARS-CoV-2 UTR's Intrudes Host RBP's and Modulates Cellular Splicing. | Adv Virol | 2023 | 37065904 | PubTator, text mining | PubMed |
| Identification of Orbivirus Non-Structural Protein 5 (NS5), Its Role and Interaction with RNA/DNA in Infected Cells. | Int J Mol Sci | 2023 | 37047816 | PubTator, text mining | PubMed |
| Molecular Docking and Dynamics Simulation Studies Predict Potential Anti-ADAR2 Inhibitors: Implications for the Treatment of Cancer, Neurological, Immunological and Infectious Diseases. | Int J Mol Sci | 2023 | 37047766 | PubTator, text mining | PubMed |
| Library Screening Reveals Sequence Motifs That Enable ADAR2 Editing at Recalcitrant Sites. | ACS Chem Biol | 2023 | 37040436 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/104/papers?page=12